Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 260 
Year : 2014  |  Volume : 20  |  Issue : 3  |  Page : 170-174

Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: A preliminary approach

1 Department of Internal Medicine, Al-Azhar University, Cairo; Egyptian Liver Fibrosis Study Group, Egypt
2 Department of Endemic Medicine and Hepatology, Cairo University, Cairo, Egypt
3 Department of Clinical and Chemical Pathology, Cairo University, Cairo, Egypt
4 Department of Public Health and Community Medicine, Cairo University, Cairo, Egypt
5 Department of Community Medicine and Public Health, Zagazig University, Zagazig, Egypt
6 Department of Internal Medicine, Al-Azhar University, Cairo, Egypt

Correspondence Address:
Dr. Mohamed Alboraie
Department of Internal Medicine, Al-Azhar University, Cairo 11651
Login to access the Email id

Source of Support: The manuscript was presented in meeting of the Asia Pacific association of liver diseases, Singapore, Saturday - June 08, 2013 08:30-17:30.,, Conflict of Interest: None

DOI: 10.4103/1319-3767.133003

Rights and Permissions

Background and Aims: Egy-Score is a new noninvasive score for prediction of severe hepatic fibrosis in patients with chronic liver diseases. The aim of this study was to validate Egy-Score as a noninvasive score for predicting stage of hepatic fibrosis in a group of Egyptian chronic hepatitis C patients. Patients and Methods: One hundred Egyptian patients with chronic hepatitis C were enrolled. Mean age was 40.25 ± 9.39 years. They were subjected to CA19-9, alpha-2-macroglobulin, total bilirubin, platelet count and albumin, liver biopsy, and histopathological staging of hepatic fibrosis according to METAVIR scoring system as part of their assessment for treatment. Egy-Score was calculated according to the following formula: Egy-Score = 3.52 + 0.0063 × CA19-9 + 0.0203 × age + 0.4485 × alpha-2-macroglobulin + 0.0303 × bilirubin - 0.0048 × platelet - 0.0462 × albumin. Egy-Score results were correlated to the stage of hepatic fibrosis. Results: Egy-Score correlates positively with the stage of hepatic fibrosis (F0-F4). Egy-Score was able to differentiate significant hepatic fibrosis, severe hepatic fibrosis, and cirrhosis accurately. Cutoff values of Egy-Score were 2.91850 (for significant fibrosis), 3.28624 (for severe fibrosis), and 3.67570 (for cirrhosis). Sensitivity, specificity, and areas-under-ROC curve (AUROCs) were 75.8%, 68.42%, and 0.776 (for significant fibrosis "≥F2"), 91.67%, 77.63%, and 0.875 (for severe fibrosis "≥F3"), and 81.82%, 86.52%, and 0.874 (for cirrhosis "F4"), respectively. Conclusion: Egy-Score is a useful noninvasive panel of surrogate biomarkers that could accurately predict different stages of hepatic fibrosis in patients with chronic hepatitis C.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded368    
    Comments [Add]    

Recommend this journal